Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart software aims to simplify HIV treatment decisions

NCT ID NCT07219862

Knowledge-focused Sponsor: Keck School of Medicine of USC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a software tool called smART that helps doctors pick the best combination of HIV drugs for each patient. The tool considers drug resistance, other health conditions, and medication safety. Researchers will compare treatment choices made with and without the tool using 250 patient cases. The goal is to see if the tool helps doctors follow guidelines more closely and make decisions faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smART (Smart Antiretroviral Therapy Assistant) software tool
What this could lead to
If successful, this tool could help general doctors make faster, more accurate HIV treatment decisions, potentially improving patient outcomes.
What could go wrong
This is a small, early-stage study using simulated patient cases, not real-world treatment. The tool may not improve outcomes or be adopted in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2028

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: HIV patients 1. Documented HIV-1 infection 2. Greater than 18 years of age 3. Genotype resistance testing previously conducted or scheduled through clinical care Providers: HIV care providers who will determine treatment selections, with or without utilizing our clinical decision support tool Exclusion Criteria: HIV patients: 1\. Refusal or inability to give informed consent Providers: 1\. Refusal to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIDS (acquired immune deficiency syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIDS (acquired immune deficiency syndrome) Antiretroviral therapy, highly active Clinical decision support system (CDSS) HIV (human immunodeficiency virus) Individualized therapy Personalized medicine Precision medicine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.